Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Expert Opin Investig Drugs
; 28(2): 107-112, 2019 Feb.
Article
en En
| MEDLINE
| ID: mdl-30507322
ABSTRACT
INTRODUCTION:
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Camptotecina
/
Inmunoconjugados
/
Anticuerpos Monoclonales Humanizados
/
Neoplasias de la Mama Triple Negativas
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Female
/
Humans
Idioma:
En
Año:
2019
Tipo del documento:
Article